Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Compugen Ltd.. (3/8/18). "Press Release: Compugen to Present at the Cowen and Company 38th Annual Health Care Conference". Holon.

Organisations Organisation Compugen Ltd. (Nasdaq: CGEN)
  Group Compugen (Group)
  Organisation 2 Columbia University Medical Center (CUMC)
  Group Columbia University New York
Products Product Cowen & Co. Annual Health Care Conference 2018 Boston
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Index terms Index term Compugen–Cowen: investor conference, 201803 supply service Compugen presents at Cowen & Co Annual Health Care Conference 2018
  Index term 2 Compugen–Burns McClellan: public relations, 201803– service existent investor relations by Burns McClellan
Persons Person Cohen-Dayag, Anat (Compugen 201112 CEO)
  Person 2 Steier, Jill (Burns McClellan 201803)
     


Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that Anat Cohen-Dayag, PhD, President and CEO of Compugen, will present a corporate overview and update at the Cowen and Company 38th Annual Health Care Conference in Boston, on Tuesday, March 13, 2018, at 10:40 AM.

A live webcast of the presentation will be available on Compugen’s website. A replay will be available after the presentation ends.

Also at the Cowen Health Care Conference, on March 14, 2018, at 12:45 PM, Charles Drake, MD, PhD, Director, Genitourinary Oncology, Co-Director Immunotherapy Program, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center and a member of Compugen’s scientific advisory board, will take part in a panel titled “Novel Immuno-Oncology Drug Candidates.”


About Compugen

Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen’s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen’s shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at http://www.cgen.com.


Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124

Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-0006

   
Record changed: 2018-04-08

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Compugen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top